Gastrointestinal stromal tumors
- 18 February 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Virchows Archiv A Pathological Anatomy and Histopathology
- Vol. 456 (2), 111-127
- https://doi.org/10.1007/s00428-010-0891-y
Abstract
Gastrointestinal stromal tumors (GISTs) have emerged from being poorly defined, treatment-resistant tumors to a well-recognized, well-understood, and treatable tumor entity within only one decade. The understanding of GIST biology has made this tumor a paradigm for molecularly targeted therapy in solid tumors and provides informative insights into the advantages and limitations of so-called targeted therapeutics. Approximately 85% of GISTs harbor activating mutations in KIT or the homologous receptor tyrosine kinase PDGFRA gene. These mutations are an early event in GIST development and the oncoproteins serve as a target for the small molecule tyrosine kinase inhibitors imatinib and sunitinib. The existing and emerging treatment options demand exact morphologic classification and risk assessment. Although, KIT (CD117) immunohistochemistry is a reliable diagnostic tool in the diagnosis of GIST, KIT-negative GISTs, GISTs showing unusual morphology as well as GISTs which progress during or after treatment with imatinib/sunitinib can be a challenge for pathologists and clinicians. This review focuses on GIST pathogenesis, morphologic evaluation, promising new immunohistochemical markers, risk assessment, the role of molecular analysis, and the increasing problem of secondary imatinib resistance and its mechanisms.Keywords
This publication has 163 references indexed in Scilit:
- Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumorsLaboratory Investigation, 2010
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisThe Lancet Oncology, 2009
- High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumorsGenes, Chromosomes and Cancer, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Risk stratification of patients diagnosed with gastrointestinal stromal tumorHuman Pathology, 2008
- Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumorsGenes, Chromosomes and Cancer, 2008
- Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumorsOncogene, 2008
- Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomasProceedings of the National Academy of Sciences of the United States of America, 2007
- Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumorProceedings of the National Academy of Sciences of the United States of America, 2006
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005